Experience

长春金赛药业有限责任公司

• China
• Biotechnology Research
• 1 - 100 Employee

• Associate Director of Protein Conjugated

  • Mar 2023 - Present

  Shanghai, China Discovery, design and development of protein or peptide long-acting sustained release platform



台耀化學股份有限公司(Formosa Laboratories, Inc.)

• Taiwan
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Assistant Manager, RD-ADC Department

  • Sep 2022 - Mar 2023

  Taoyuan City, Taiwan 1. Manage the ADC team and lead the planning, evaluation and execution of CMC strategy and process development for all ADC pipeline products, including but not limited to contract manufacturer technology transfer, formulation development, process development, analytical method development and validation to ensure cGMP compliance and regulatory requirements. 2. Coordinate R&D/CMO/CDMO small molecule and ADC project management, resource planning and timeline. 3. Communicate with other… Show more 1. Manage the ADC team and lead the planning, evaluation and execution of CMC strategy and process development for all ADC pipeline products, including but not limited to contract manufacturer technology transfer, formulation development, process development, analytical method development and validation to ensure cGMP compliance and regulatory requirements. 2. Coordinate R&D/CMO/CDMO small molecule and ADC project management, resource planning and timeline. 3. Communicate with other departments (ARD, INJ, PD, QC and MSD) to expedite ADC project timelines. Human resource leaderships: 2 Ph.D. and 6 M.S. Researchers.

• Primary Investigator / Researcher II, RD-ADC Department

  • May 2021 - Sep 2022

  1. Leader as two major antibody drug conjugate projects： a. KADCYLA biosimilar： - Process optimization of anti-HER2 KADCYLA biosimilar - Conduct the CMC of Anti-HER2 antibody-drug conjugate (ADC) - Cooperate with ARD, PD, and QC to scale up the ADC DS to 44.69g Engineering Batch, 128.70g Trial Batch, 132.35g Trial Batch, and 154.96g CTM (Clinical Trial Material) batch. b. Antibody-drug conjugate through cysteine residue with cytolysin-based payload linker - Process… Show more 1. Leader as two major antibody drug conjugate projects： a. KADCYLA biosimilar： - Process optimization of anti-HER2 KADCYLA biosimilar - Conduct the CMC of Anti-HER2 antibody-drug conjugate (ADC) - Cooperate with ARD, PD, and QC to scale up the ADC DS to 44.69g Engineering Batch, 128.70g Trial Batch, 132.35g Trial Batch, and 154.96g CTM (Clinical Trial Material) batch. b. Antibody-drug conjugate through cysteine residue with cytolysin-based payload linker - Process optimization of anti-FAPα antibody-drug conjugate (ADC) - Conduct the CMC of anti-FAPα antibody-drug conjugate (ADC) - Cooperate with ARD, PD, and QC to scale up the ADC DS to 130g, 154g, and 382g CTM batch. 2. Discovery and development of antibody-drug conjugate (ADC) platform - Development of antibody-drug conjugate through cysteine residue with different payload linkers (low and high DAR value). - ADC platform verification with different antibodies. 3. CDMO (Contract Development and Manufacturing Organization). Human resource leaderships: 1 Ph.D. and 3 M.S. Researchers.



Senhwa Biosciences, Inc.

• United States
• Biotechnology
• 1 - 100 Employee

• CMC team Project Manager

  • Mar 2021 - May 2021

  1. Join the CMC of CX-5461 and CX-4945 2. Cooperated with pre-clinical and clinical team 3. Design and discovery 2nd generation of G4 stabilizer Human resource leaderships: 1 M.S. Researcher.



CHO Pharma.INC

• Project Coordinator & Researcher II

  • Feb 2014 - Mar 2021

  Taipei City, Taiwan 1. Development of globo-series carbohydrate-based vaccines against cancer： - Chemo-enzymatic synthesis of library of diverse globo-series glycans and glycosphingolipid synthesis 2. Development of Biotinylated and Magnetic Bead-Immobilized endoglycosidases for the efficient glyco-engineering of antibodies - Process development of efficient glyco-engineering of antibodies 3. Development of platform for antibody-drug conjugate (ADC) - Designed and synthesized diverse… Show more 1. Development of globo-series carbohydrate-based vaccines against cancer： - Chemo-enzymatic synthesis of library of diverse globo-series glycans and glycosphingolipid synthesis 2. Development of Biotinylated and Magnetic Bead-Immobilized endoglycosidases for the efficient glyco-engineering of antibodies - Process development of efficient glyco-engineering of antibodies 3. Development of platform for antibody-drug conjugate (ADC) - Designed and synthesized diverse b-Glucuronide linker drug candidates - Development of site-specific antibody-drug conjugation through glycoengineering - ADC platform verification and patent filling 4. Conduct the CMC of Anti-HER2 antibody-drug conjugate (ADC) - Process optimization of b-Glucuronide linker drug candidate - Performing medium scale synthesis to execute chemistry route, estimate the time course for technical transfer to the CRO. 5. Foster collaborative relationships within and outside CGMH: - Performing small scale synthesis to conduct anti-EGFR vIII ADC for Glioblastoma Multiforme (GBM), estimate the efficacy to combine with BBB (blood brain barrier) opening test. 6. Development of Klebsiella pneumoniae capsule polysaccharide conjugated vaccines (Kp vaccines) Show less



Academia Sinica, Taiwan

• Taiwan
• Higher Education
• 700 & Above Employee

• Postdoctoral Researcher (Dr. Chi-Huey Wong)

  • Nov 2013 - Feb 2014

  Taiwan 1. Design the synthetic route for hepta-saccharide 2. Synthesis of the hepta-saccharide for prostate cancer antigen 3. Development of Carbohydrate-Based Vaccine against prostate cancer



Academia Sinica, Taiwan

• Taiwan
• Higher Education
• 700 & Above Employee

• Research Assistant (Dr. Chung-Yi Wu)

  • Jul 2008 - Aug 2009

  Taiwan 1. Chemical synthesis of building blocks for total synthesis of carbohydrate antigen 2. Purification of the oligosaccharide by HPLC and characterized its structure by NMR and MS.